Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Clinical trial NCT06514534 · RECRUITING

Trial details

NCT number: NCT06514534
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myeloid Leukemia (CML)

Start date: 2025-02-18
Primary completion: 2029-02-17
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.